KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Q3 2025 value amounting to -$9.4 million.

  • Aurinia Pharmaceuticals' Change in Receivables fell 18542.1% to -$9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.8 million, marking a year-over-year decrease of 29336.98%. This contributed to the annual value of $12.5 million for FY2024, which is 1743.35% up from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Change in Receivables is -$9.4 million, which was down 18542.1% from -$259000.0 recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Change in Receivables high stood at $23.6 million for Q3 2022, and its period low was -$28.3 million during Q4 2022.
  • Moreover, its 5-year median value for Change in Receivables was $3.2 million (2021), whereas its average is $1.6 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Change in Receivables soared by 33724.29% in 2022, and later crashed by 84113.79% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Change in Receivables (Quarter) stood at $5.6 million in 2021, then plummeted by 605.05% to -$28.3 million in 2022, then skyrocketed by 51.01% to -$13.9 million in 2023, then surged by 100.44% to $61000.0 in 2024, then crashed by 15449.18% to -$9.4 million in 2025.
  • Its Change in Receivables stands at -$9.4 million for Q3 2025, versus -$259000.0 for Q2 2025 and $3.8 million for Q1 2025.